Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB0022 in healthy volunteers and Parkinson's disease
NCT04867642Phase 1Completed
- Sponsor
- UCB
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glovadalen in Parkinson's disease (PD) (7 arms), sponsored by UCB. Primary endpoint: Treatment-Emergent Adverse Events. Started Apr 2021; status: completed.
02
Drugs
glovadalen
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04867642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04867642.